Arcellx Q3 net loss $39.3M vs $92.9M prior year; cash $482.7M; CART-ddBCMA data at ASH with 22mo follow-up

Arcellx, Inc.

2023-Q3 EPS reported -$1.89 revenue$47,171,000

Net loss narrowed to $39.3M from $92.9M in Q3 2022; collaboration revenue $15.0M from Kite license.
Cash, equivalents and marketable securities $482.7M; company expects to fund operations into 2026.
CART-ddBCMA Phase 1 data: median DOR, PFS and OS not reached at 22-month median follow-up; no delayed neurotoxicity.
Upcoming ASH oral presentation on Dec 11, 2023 with new data at median 26.5-month follow-up.
R&D expenses $43.8M (down from $83.5M) primarily due to non-cash charge for Lonza manufacturing agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Arcellx, Inc. reported third quarter ended September 30, 2023 results: revenue $15.0 million, net income Net loss was $39.3 million.

Period: third quarter ended September 30, 2023
Revenue: $15.0 million
Net income: Net loss was $39.3 million
Result: reported results

Exact text from the filing

million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026. Collaboration revenue: Collaboration revenue was $15.0 million and zero for the quarters ended September 30, 2023 and 2022, respectively. The revenue results for the three months ended September 30, 2023 is from the recognition of research

View on SEC.gov

Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.